Zepbound

Latest four-week snapshot through 2026-08-05 · 1 wave. Use the controls above to change the window.

GLP-1 Medications · 1 wave · n=72 answers, pooled

By assistant

How often each assistant brings the brand up in recommendation answers.

Share of recommendations over time

Wave-by-wave share of recommendation answers that named this brand.

What they call it

Recurring descriptions in the assistants' own words, grouped by theme.

• fda-approved for weight management ×32

  “* **FDA Approval:** Zepbound is specifically FDA-approved for chronic weight management (for adults with obesity, or those who are overweight with at least one weight-related condition).”

• weekly dosing ×29

  “They are administered as a weekly injection, have the same side effects, and come in the exact same doses (ranging from 2.”

• dual gip/glp-1 agonist ×25

  “If you are looking to lose weight, **Zepbound (tirzepatide)** is the superior choice by a wide margin.”

• greater weight loss ×25

  “Zepbound (injectable): ~22.5% average weight loss.”

• fda-approved ×18

  “Because they are FDA-approved for entirely different medical conditions, choosing the wrong one could mean your insurance won't cover it or you won't get the specific health benefits you need.”

• tirzepatide ×17

  “If you are eligible for either and the deciding goal is **the greatest average weight loss**, choose Zepbound (tirzepatide).”

• once-weekly injection ×14

  “Newer, once-weekly injections are generally more effective for weight loss than Saxenda and may end up being cheaper depending on your insurance or manufacturer savings cards.”

• chronic weight management ×11

  “If you do not have Type 2 diabetes and your goal is chronic weight management, **Zepbound** is the correct choice.”

• most effective weight-loss medications ×10

  “Patients lose an average of **20%+ of their body weight**. Wegovy and Zepbound only require **once-weekly** injections.”

• injectable option ×9

  “* **Excellent for Weight Maintenance:** If you have already lost weight using highly potent injectable GLP-1s (like Wegovy or Zepbound) but want to transition off weekly shots, clinical trials (such as the *ATTAIN-MAINTAIN* trial) show that switching to Foundayo is highly effecti”

In their words

243 exact quoted mentions in this snapshot, grouped by coded tone.

What they recommend

“tirzepatide (Mounjaro/Zepbound) tends to show greater average weight loss in trials than semaglutide”

“**Zepbound** (tirzepatide) – weekly injection, dual GLP-1/GIP agonist”

“**Zepbound** – approved for weight management (dual GLP-1/GIP agonist)”

“**Zepbound** (tirzepatide) – weekly injection; dual GLP-1/GIP agonist, often shows greater average weight loss than semaglutide in trials”

“tirzepatide-based drugs (Mounjaro/Zepbound) have shown greater average weight loss in trials than semaglutide-based ones”

Where they hedge

“**Tirzepatide** – sold as Mounjaro (diabetes) and Zepbound (weight loss); a dual GLP-1/GIP agonist”

“**Tirzepatide** – sold as **Zepbound** (weight loss)”

“FDA-approved brand-name drugs (Ozempic, Wegovy, Mounjaro, Zepbound) These went through rigorous clinical trials and FDA review, so their core efficacy/safety data is credible. But that doesn't mean all their *marketing* is beyond reproach”

“"Same as Ozempic/Wegovy/Zepbound" or "generic" for a compounded product.”

“Examples include products such as Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda.”

What they warn about

“Novo Nordisk is currently suing Eli Lilly over Zepbound ads. The ads compare Lilly's Zepbound with Novo's Wegovy, and Novo argues they give consumers a misleading picture of how the drugs compare”

“The dispute centers on dosing comparisons: Eli Lilly says its ads are based on the SURMOUNT-5 trial, completed in 2024, which compared patients on 10 or 15 milligrams of Zepbound to patients on 1.7 mg or 2.4 mg doses of Wegovy.”

“**Wegovy** and **Zepbound** may be more effective for many people and are weekly rather than daily injections, but without coverage they are often still expensive.”

The substitution map

Which competitors assistants suggest when shoppers ask for something cheaper.

Where this comes from

39 of 244 mentions appear alongside an identifiable web citation. Citation does not establish causation.

Where they send you

Stores and sites assistants name as places to buy this brand.

Method: fixed shopper questions asked repeatedly to Claude, OpenAI GPT and Gemini with web search on. Shares are the percentage of recommendation answers mentioning the brand. Quotes are AI outputs; full transcripts are kept as receipts.